| Warfarin | venous thrombosis, in all type of patients | vs 1.5 months | VTE by 48% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| VTE | 0.52 [0.35 0.78] | p=0.04 | 0 | 897 | 1 | Schulman, | | puylmonary embolism | no data | | Major bleeding | 4.88 [0.57 41.93] | p=1.00 | 0 | 897 | 1 | Schulman, | | All cause death | 0.75 [0.39 1.44] | p=1.00 | 0 | 897 | 1 | Schulman, |
| Trial | Studied treatment | Control | Patients |
|---|
| Schulman, 1995 | 6 months treatment with warfarin or dicoumarol adjusted for a target INR between 2.0 - 2.85 | 1.5 months warfarin or dicoumarol adjusted for a target INR between 2.0 - 2.85 | |
| |
| Warfarin | | vs 1.5-3 months | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| VTE | 1.17 [0.66 2.10] | p=1.00 | 0 | 736 | 1 | Pinede, | | puylmonary embolism | no data | | Major bleeding | 1.73 [0.62 4.81] | p=1.00 | 0 | 736 | 1 | Pinede, | | All cause death | 1.32 [0.59 2.95] | p=1.00 | 0 | 736 | 1 | Pinede, |
| Trial | Studied treatment | Control | Patients |
|---|
| Pinede, 2001 | Long course of therapy (6 months for proximal DVT and/or PE; 12 weeks for calf DVT) by fluindione adjusted for INR range of 2.0 to 3.0 | Short oral anticoagulant course (3 months for proximal DVT and/or PE; 6 weeks for isolated calf
DVT) by fluindione adjusted for INR range of 2.0 to 3.0 | |
| |
| Warfarin | | vs discontinuation | Major bleeding by 175% adverse event VTE by 46% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| VTE | 0.54 [0.38 0.75] | p=0.04 | 0 | 1869 | 7 | Levine, LAFIT (Kearon), Agnelli, Agnelli, PREVENT (Ridker), ELAET (Kearon), DURAC (Schulman), | | puylmonary embolism | 1.65 [0.39 7.07] | p=1.00 | 0 | 267 | 1 | Agnelli, | | Major bleeding | 2.75 [1.29 5.86] | p=0.04 | 0 | 1869 | 7 | Levine, LAFIT (Kearon), Agnelli, Agnelli, PREVENT (Ridker), ELAET (Kearon), DURAC (Schulman), | | All cause death | 0.86 [0.56 1.33] | p=1.00 | 0 | 1869 | 7 | Levine, LAFIT (Kearon), Agnelli, Agnelli, PREVENT (Ridker), ELAET (Kearon), DURAC (Schulman), |
| Trial | Studied treatment | Control | Patients |
|---|
| Levine, 1995 | continuation for 2 months of warfarin adjusted INR value of 2.0 to 3.0 | Discontinue oral anticoagulant therapy (after 1 months) | Patients with venographically confirmed acute proximal DVT who had received four weeks of warfarin after initial heparin and whose four week IPG was normal | | LAFIT (Kearon), 1999 | Continuation of the oral anticoagulant therapy up to 24 months,
warfarin was adjusted to achieve
a target INR between 2.0 and 3.0. | discontinuation (after 3 months) | patients who had completed 3 months of anticoagulant therapy for a first episode of idiopathic venous thromboembolism | | Agnelli, 2001 | continuation for 9 additional months; warfarin or acenocoumarol adjusted to achieve a target INR between 2.0 and 3.0 | discontinuation (after 3 months months) | Patients with a first episode of idiopathic proximal deep venous thrombosis who had completed three months of oral anticoagulant therapy | | Agnelli, 2003 | continuation for 3 or 9 additionnal months of warfarin or other oral anticoagulant was adjusted to achieve a target INR between 2.0 and 3.0. | discontinuation (after 3 months) | patients who had had 3 months of oral anticoagulant therapy without experiencing recurrence or bleeding after a first episode of pulmonary embolism | | PREVENT (Ridker), 2003 | extension with low-intensity warfarin (target INR, 1.5 to 2.0) | placebo | Patients with idiopathic venous thromboembolism who had received full-dose anticoagulation therapy for a median of 6.5 months | | ELAET (Kearon), 2004 | continuation for 2 additionnal months of warfarin adjusted to achieve
a target INR between 2.0 and 3.0. | discontinuation (after 1 months) | | | DURAC (Schulman), 1997 | indefinite warfarin or dicoumarol adjusted for a target INR between 2.0 and 2.85 | 6 months warfarin or dicoumarol adjusted for a target INR between 2.0 and 2.85 | |
| |
| Bemiparin | venous thrombosis, in all type of patients | vs warfarin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 0.78 [0.18 3.31] | p=1.00 | 0 | 324 | 1 | Kakkar, | | VTE during follow-up after active anticoagulant treatment | no data | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Kakkar, 2003 | LMWH, 115 IU/kg qd followed by Bemiparin 3,500 IU qd | A: UFH, 30/40,000IU qd; B: LMWH, 115 IU/kg qd followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT by Venography/compression ultrasonography |
| |
| Dalteparin | acute coronary syndrome, in all type of patients | vs placebo (on top of aspirin) | myocardial infarction or death by 23% suggested myocardial infarction (fatal and non fatal) by 33% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death, myocardial infarction, or recurrent at 14 days | no data | | death, myocardial infarction, or recurrent at 30 days | no data | | death at 30 days | no data | | myocardial infarction at 30 days | no data | | myocardial infarction or death | 0.77 [0.60 0.98] | p=0.04 | 0 | 4473 | 3 | FRISC (long term), FRISC (short term), FRIC prolonged treatment phase (LWMH vs PBO), | | recurrent angina | 1.12 [0.83 1.51] | p=1.00 | 0 | 1482 | 1 | FRIC prolonged treatment phase (LWMH vs PBO), | | myocardial infarction (fatal and non fatal) | 0.67 [0.51 0.87] | p=0.04 | 0 | 4473 | 3 | FRISC (long term), FRIC prolonged treatment phase (LWMH vs PBO), FRISC (short term), | | Revascularization | 0.87 [0.71 1.07] | p=1.00 | 0 | 4473 | 3 | FRISC (long term), FRIC prolonged treatment phase (LWMH vs PBO), FRISC (short term), | | All cause death | 1.09 [0.72 1.65] | p=1.00 | 0 | 4473 | 3 | FRISC (long term), FRIC prolonged treatment phase (LWMH vs PBO), FRISC (short term), | | Drop in platelet count of 50% | no data | | stroke (fatal and non fatal) | no data | | Minor bleeding | no data | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| FRISC (long term), 1996 | dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin | matched placebo + aspirin | patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours | | FRIC prolonged treatment phase (LWMH vs PBO), 1997 | dalteparin SC 120 i.u./kg twice-daily for 6 days followed by dalteparin 7500UI daily up to day 45 (+aspirin) | unfractionated heparin dose-adjusted intravenous infusion (for at least 48h) then by subcutaneous injection up to day 6 (then placebo) (+aspirin)
| Patients with unstable angina or non-Q-wave myocardial infarction
| | FRISC (short term), 1996 | dalteparin SC 120 IU per kg bodyweight [maximum 10 000 IU] twice daily for 6 days with 7500 IU once daily for 34-45 days +aspirin
| matched placebo + aspirin
| patients with unstable CAD (unstable angina or non-Q-wave myocardial infarction) within the previous 72 hours
|
| |
| Dalteparin | | vs UFH (on top of aspirin) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death, myocardial infarction, or recurrent at 14 days | no data | | death, myocardial infarction, or recurrent at 30 days | no data | | death at 30 days | no data | | myocardial infarction at 30 days | no data | | myocardial infarction or death | 1.09 [0.63 1.86] | p=1.00 | 0 | 1482 | 1 | FRIC (acute phase LMWH vs UFH), | | recurrent angina | no data | | myocardial infarction (fatal and non fatal) | 0.80 [0.43 1.49] | p=1.00 | 0 | 1482 | 1 | FRIC (acute phase LMWH vs UFH), | | Revascularization | 0.90 [0.56 1.43] | p=1.00 | 0 | 1482 | 1 | FRIC (acute phase LMWH vs UFH), | | All cause death | 3.57 [0.99 12.85] | p=1.00 | 0 | 1482 | 1 | FRIC (acute phase LMWH vs UFH), | | Drop in platelet count of 50% | no data | | stroke (fatal and non fatal) | no data | | Minor bleeding | no data | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| FRIC (acute phase LMWH vs UFH), 1997 | twice-daily weight-adjusted subcutaneous injections of dalteparin (120 i.u./kg) (+aspirin)
| dose-adjusted intravenous infusion of unfractionated heparin (+aspirin)
| Patients with unstable angina or non-Q-wave myocardial infarction
|
| |
| Dalteparin | thrombosis prevention, in general surgery | vs placebo | asymptomatic DVT by 74% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.19 [0.01 3.93] | p=1.00 | 0 | 197 | 1 | Ockelford , | | asymptomatic DVT | 0.26 [0.08 0.84] | p=0.04 | 0 | 183 | 1 | Ockelford , | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 4.66 [0.22 98.28] | p=1.00 | 0 | 197 | 1 | Ockelford , | | transfusion | no data | | Bleeding | 2.33 [0.70 7.69] | p=1.00 | 0 | 197 | 1 | Ockelford , | | Major bleeding | 0.93 [0.23 3.83] | p=1.00 | 0 | 197 | 1 | Ockelford , | | All cause death | 0.19 [0.01 3.93] | p=1.00 | 0 | 197 | 1 | Ockelford , |
| Trial | Studied treatment | Control | Patients |
|---|
| Ockelford , 1989 | Dalteparin 2500 anti-Xa units | Placebo | general surgery |
| |
| Dalteparin | | vs unfractionated heparin | wound haematoma / infection by 49% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 1.21 [0.66 2.22] | p=1.00 | 0 | 3961 | 2 | Borstad, Kakkar, | | asymptomatic DVT | 0.90 [0.63 1.29] | p=1.00 | 0 | 2764 | 10 | Bergqvist, Onarheim, Koller, Fricker, Bergqvist, Caen, Borstad, Briel, Creperio, Hartl, | | Symptomatic venous thromboembolism (DVT, PE) | 0.37 [0.07 2.10] | p=1.00 | 0 | 335 | 3 | Fricker, Borstad, Creperio, | | wound haematoma / infection | 0.51 [0.33 0.79] | p=0.04 | 0 | 3961 | 2 | Borstad, Kakkar, | | transfusion | 1.09 [0.89 1.33] | p=1.00 | 0 | 2262 | 6 | Bergqvist, Koller, Koller, Bergqvist, Caen, Hartl, | | All cause death | 1.26 [0.93 1.72] | p=1.00 | 0 | 5843 | 8 | Onarheim, Koller, Koller, Bergqvist, Caen, Hartl, Borstad, Kakkar, | | Bleeding | 0.94 [0.80 1.11] | p=1.00 | 0 | 6570 | 11 | Bergqvist, Onarheim, Koller, Koller, Fricker, Bergqvist, Caen, Borstad, Hartl, Borstad, Kakkar, | | Major bleeding | 0.92 [0.70 1.22] | p=1.00 | 0 | 5568 | 10 | Bergqvist, Onarheim, Koller, Koller, Fricker, Caen, Borstad, Hartl, Borstad, Kakkar, |
| Trial | Studied treatment | Control | Patients |
|---|
| Bergqvist, 1986 | Dalteparin 5000 | UFH 10 000 units | Abdominal surgery | | Onarheim, 1986 | Dalteparin 5000 | UFH 10 000 units | Abdominal surgery | | Koller, 1986 | Dalteparin 7500 | UFH 10 000 units | Abdominal surgery | | Koller, 1986 | Dalteparin 2500 | UFH 10 000 units | Abdominal surgery | | Fricker, 1988 | Dalteparin 5000 | UFH 15 000 units | Abdominopelvic surgery | | Bergqvist, 1988 | Dalteparin 5000 | UFH 10 000 units | Abdominal surgery | | Caen, 1988 | Dalteparin 2500 | UFH 10 000 units | Abdominal surgery | | Borstad, 1988 | Dalteparin 5000 | UFH 10 000 units | Gynaecological surgery | | Briel, 1988 | Dalteparin 5000 | UFH 10 000 units+DHE | Gynaecological surgery | | Creperio, 1990 | Dalteparin 2500 | UFH 10 000 units | General surgery | | Hartl, 1990 | Dalteparin 2500 | UFH 10 000 units | Abdominal surgery | | Borstad, 1992 | Dalteparin 2500 anti Xa units | UFH 10 000 units | Gynaecological surgery | | Kakkar, 1993 | Dalteparin 2500 anti Xa units | UFH 10 000 units | Abdominal surgery |
| |
| Dalteparin | thrombosis prevention, in orthopedic surgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Jorgensen, 1989 | dalteparin 5000 x1 | Placebo | Hip fracture | | Torholm, 1991 | dalteparin 5000x1 | Placebo | Elective hip |
| |
| Dalteparin | | vs Dextran | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Eriksson , 1988 | dalteparin | Dextran | Elective hip | | Matzsch , 1988 | dalteparin | Dextran | Elective hip | | Matzsch , 1991 | dalteparin | Dextran | Elective hip |
| |
| Dalteparin | | vs Unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Haas , 1985 | dalteparin | Unfractionated heparin | Elective hip | | Binsack , 1986 | dalteparin | Unfractionated heparin | Elective hip | | Barre , 1987 | dalteparin | Unfractionated heparin | Elective hip | | Dechavanne , 1989 | dalteparin | Unfractionated heparin | Elective hip | | Eriksson , 1989 | dalteparin | Unfractionated heparin | Elective hip | | Monreal , 1989 | dalteparin | Unfractionated heparin | Hip |
| |
| Dalteparin | venous thrombosis, in all type of patients | vs warfarin | VTE during active anticoagulant treatment by 42% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 0.58 [0.36 0.93] | p=0.04 | 0 | 777 | 2 | Das, Lee, | | VTE during follow-up after active anticoagulant treatment | no data | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Das, 1996 | UFH followed by Dalteparin 5,000 IU qd | UFH followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT by Venography | | Lee, 2003 | LMWH, 200 IU/kg qd followed by Dalteparin 150 IU/kg qd | LMWH, 200 IU/kg qd followed by Warfarin target INR 2-3 | patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography |
| |
| Dalteparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 1.21 [0.49 2.97] | p=1.00 | 0 | 434 | 4 | Bratt et al , Holm et al , Bratt et al, Lindmarker et al , | | Thrombus extension | 0.59 [0.25 1.43] | p=1.00 | 0 | 434 | 4 | Bratt et al , Holm et al , Bratt et al, Lindmarker et al , | | All cause death | 1.38 [0.57 3.30] | p=1.00 | 0 | 434 | 4 | Bratt et al , Holm et al , Bratt et al, Lindmarker et al , | | Short term haemorrhage | 1.17 [0.21 6.42] | p=1.00 | 0 | 434 | 4 | Bratt et al , Holm et al , Bratt et al, Lindmarker et al , |
| Trial | Studied treatment | Control | Patients |
|---|
| Bratt et al , 1985 | Dalteparin Intravenousv (ajusted) for >=5 Days, 120 U/kg BID | unfractionated heparin intravenous APPTx1.7-3.5 | | | Holm et al , 1986 | Dalteparin Subcutaneous twice daily ajusted for 7 Days, 57-107 U/kg BID | unfractionated heparin subcutaneous twice daily 16000-30000 U | | | Bratt et al, 1990 | Dalteparin Subcutaneous twice daily ajusted for >= 5 Days, 120 U/kg BID | unfractionated heparin intravenous APPTx2-4 | | | Lindmarker et al , 1993 | Dalteparin Subcutaneous once daily for >= 5 Days, 200 U/kg BID | unfractionated heparin intravenous APPTx1.5-3 | |
| |
| Dalteparin | | vs twice daily dalteparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | All cause death | 2.53 [0.26 24.90] | p=1.00 | 0 | 140 | 1 | Partsch, | | Bleeding | 0.95 [0.10 9.31] | p=1.00 | 0 | 227 | 2 | Holmström, Partsch, |
| Trial | Studied treatment | Control | Patients |
|---|
| Holmström, 1992 | once daily dalteparin 200 U (anti-FXa)/kg for at least 5 days | twice daily dalteparin 100
U (anti-FXa)/kg for at least 5 days | Patients with a first occurence of DVT in the lower limb, confirmed with phlebographytio | | Partsch, 1996 | Fragmin administered 200 IU/kg once daily for at least 7 days | Fragmin 100 IU/kg twice daily for at least 7 days | patients presented with DVT extending into the iliofemoral segment diagnosed by duplex ultrasonographyA |
| |
| Ardeparin | thrombosis prevention, in orthopedic surgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Levine, 1996 | ardeparin 50/kgx2 +elastic stockings | Placebo+elastic stockings | Knee |
| |
| Ardeparin | thrombosis prevention, in general surgery | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.52 [0.03 8.33] | p=1.00 | 0 | 904 | 1 | Godwin, | | asymptomatic DVT | 0.07 [0.00 1.44] | p=1.00 | 0 | 904 | 1 | Godwin, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | All cause death | no data | | Bleeding | 1.38 [0.82 2.33] | p=1.00 | 0 | 904 | 1 | Godwin, | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Godwin, 1993 | Ardeparin 90 and 50 units/kg b.i.d | UFH 10 000 units | Abdominopelvic surgery |
| |
| Certoparin | thrombosis prevention, in orthopedic surgery | vs Unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Haas , 1987 | Sandoz +0.5mg DHE | Unfractionated heparin | Elective hip | | Lassen, 1988 | certoparin 3000+0.5mg DHE, x1 | Placebo | Elective hip | | Lassen, 1989 | certoparin 3000+0.5mg DHE x1 | placebo | Hip fracture |
| |
| Certoparin | thrombosis prevention, in general surgery | vs unfractionated heparin | Bleeding by 42% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.97 [0.56 1.68] | p=1.00 | 0 | 24801 | 5 | Schielke, Koppenhagen, Hoffmann and Largiader, Heilmann, Haas, | | asymptomatic DVT | 0.86 [0.63 1.17] | p=1.00 | 0 | 2921 | 11 | Schmitz-Huebner, Sasahara, Voigt, Welzel, Kakkar, Adolf, Heilmann, Baumgartner, Koppenhagen, Koppenhagen, Heilmann, | | Symptomatic venous thromboembolism (DVT, PE) | 0.27 [0.02 3.03] | p=1.00 | 0 | 326 | 2 | Schmitz-Huebner, Voigt, | | wound haematoma / infection | 2.79 [0.25 30.92] | p=1.00 | 0 | 777 | 2 | Koppenhagen, Koppenhagen, | | transfusion | 0.98 [0.72 1.33] | p=1.00 | 0 | 879 | 3 | Sasahara, Voigt, Adolf, | | All cause death | 1.07 [0.86 1.32] | p=1.00 | 0 | 24981 | 8 | Sasahara, Voigt, Baumgartner, Koppenhagen, Schielke, Koppenhagen, Heilmann, Haas, | | Bleeding | 0.58 [0.39 0.87] | p=0.04 | 0 | 737 | 3 | Voigt, Kakkar, Heilmann, | | Major bleeding | 0.84 [0.58 1.23] | p=1.00 | 0 | 3076 | 10 | Schmitz-Huebner, Voigt, Kakkar, Heilmann, Baumgartner, Hoffmann and Largiade, Koppenhagen, Schielke, Hoffmann and Largiader, Heilmann, |
| Trial | Studied treatment | Control | Patients |
|---|
| Schmitz-Huebner, 1984 | Certoparin (dose 1 and dose 2) b.i.d. | UFH 10 000 units | Abdominal surgery | | Sasahara, 1986 | Certoparin 3000 + DHE | UFH 10 000 units +DHE | Abdominal surgery | | Voigt, 1986 | Certoparin 3000 + DHE | UFH 10 000 units | Abdominal surgery | | Welzel, 1988 | Certoparin 2500 + DHE | UFH 10 000 units+DHE | Abdominal surgery | | Kakkar, 1989 | Certoparin 3000 + DHE | UFH 10 000 units+DHE | Abdominal surgery | | Adolf, 1989 | Certoparin 3000 | UFH 15 000 units | Abdominal surgery | | Heilmann, 1989 | Certoparin 3000 | UFH 15 000 units | Gynaecological surgery | | Baumgartner, 1989 | Certoparin 3000 + DHE | UFH 5 000 units+DHE | Abdominal surgery | | Hoffmann and Largiade, 1990 | Certoparin 3000 + DHE | UFH 10 000 units | Abdominal surgery | | Koppenhagen, 1990 | Certoparin 3000 anti Xa units | UFH 15 000 units | Abdominal surgery | | Schielke, 1991 | Certoparin 3000 anti Xa units + DHE | UFH 10 000 units + DHE | Abdominal surgery | | Koppenhagen, 1992 | Certoparin 3000 anti Xa units | UFH 15 000 units | Abdominal surgery | | Hoffmann and Largiader, 1992 | Certoparin 3000 anti Xa units | UFH 10 000 units | Abdominothoracic surgery | | Heilmann, 1997 | Certoparin 3000 anti Xa units | UFH 15 000 units | Gynaecological and breast surgery | | Haas, 1999 | Certoparin 3000 anti Xa units | UFH 15 000 units | General surgery |
| |
| Fraxiparin | thrombosis prevention, in general surgery | vs placebo | Major bleeding by 151% adverse event Symptomatic venous thromboembolism (DVT, PE) by 71% suggested wound haematoma / infection by 88% suggested transfusion by 65% suggested Bleeding by 109% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.25 [0.05 1.18] | p=1.00 | 0 | 4498 | 1 | Pezzuoli, | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | 0.29 [0.11 0.80] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | wound haematoma / infection | 1.88 [1.52 2.33] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | transfusion | 1.65 [1.32 2.07] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | Bleeding | 2.09 [1.76 2.50] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | Major bleeding | 2.51 [1.89 3.34] | p=0.04 | 0 | 4498 | 1 | Pezzuoli, | | All cause death | 0.45 [0.19 1.03] | p=1.00 | 0 | 4498 | 1 | Pezzuoli, |
| Trial | Studied treatment | Control | Patients |
|---|
| Pezzuoli, 1989 | Nadroparin 2850 anti-Xa units | Placebo | general surgery |
| |
| Fraxiparin | thrombosis prevention, in orthopedic surgery | vs Unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Leyvraz, 1991 | Fraxiparin | Unfractionated heparin | Elective hip |
| |
| Reviparin | thrombosis prevention, in general surgery | vs unfractionated heparin | wound haematoma / infection by 44% suggested Bleeding by 31% suggested Major bleeding by 69% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.34 [0.03 3.25] | p=1.00 | 0 | 1351 | 1 | Kakkar, | | asymptomatic DVT | 1.10 [0.65 1.86] | p=1.00 | 0 | 1311 | 1 | Kakkar, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 0.56 [0.35 0.90] | p=0.04 | 0 | 1351 | 1 | Kakkar, | | transfusion | no data | | All cause death | 0.61 [0.14 2.55] | p=1.00 | 0 | 1351 | 1 | Kakkar, | | Bleeding | 0.69 [0.48 1.00] | p=0.04 | 0 | 1351 | 1 | Kakkar, | | Major bleeding | 0.31 [0.10 0.96] | p=0.04 | 0 | 1351 | 1 | Kakkar, |
| Trial | Studied treatment | Control | Patients |
|---|
| Kakkar, 1993 | Reviparin 1750 anti Xa units | UFH 10 000 units | General and gynaecological surgery |
| |
| Tinzaparin | thrombosis prevention, in orthopedic surgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Lassen, 1991 | tinzaparin 50/kg x1 +elastic stockings | Placebo+elastic stockings | Elective hip |
| |
| Tinzaparin | thrombosis prevention, in general surgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.35 [0.01 8.87] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | asymptomatic DVT | 0.35 [0.09 1.41] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 1.05 [0.02 54.31] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | transfusion | no data | | Bleeding | 5.26 [0.24 113.14] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | Major bleeding | 3.15 [0.12 79.84] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], | | All cause death | 0.21 [0.01 4.53] | p=1.00 | 0 | 80 | 1 | Bergqvist [42], |
| Trial | Studied treatment | Control | Patients |
|---|
| Bergqvist [42], | Tinzaparin 3500 anti-Xa units | Placebo | |
| |
| Tinzaparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 1.25 [0.24 6.45] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, | | asymptomatic DVT | 1.64 [0.70 3.85] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | All cause death | 1.11 [0.50 2.45] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, | | Bleeding | no data | | Major bleeding | 0.78 [0.40 1.55] | p=1.00 | 0 | 1290 | 1 | Leizorovicz, |
| Trial | Studied treatment | Control | Patients |
|---|
| Leizorovicz, 1991 | Tinzaparin 2500 and 3500 anti Xa units | UFH 10 000 units | Abdominothoracic and gynaecological surgery |
| |
| Tinzaparin | venous thrombosis, in all type of patients | vs acenocoumarol | recurrent DVT by 79% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.47 [0.17 1.29] | p=1.00 | 0 | 241 | 1 | Romera, | | puylmonary embolism | 1.37 [0.30 6.24] | p=1.00 | 0 | 241 | 1 | Romera, | | recurrent DVT | 0.21 [0.04 0.96] | p=0.04 | 0 | 241 | 1 | Romera, | | VTE during active anticoagulant treatment | 0.73 [0.23 2.37] | p=1.00 | 0 | 241 | 1 | Romera, | | VTE during follow-up after active anticoagulant treatment | 0.17 [0.02 1.44] | p=1.00 | 0 | 241 | 1 | Romera, | | Bleeding | 0.34 [0.04 3.33] | p=1.00 | 0 | 241 | 1 | Romera, |
| Trial | Studied treatment | Control | Patients |
|---|
| Romera, 2009 | tinzaparin SC 175 IU anti-Xa per kg once daily for 6 months | acenocoumarol for target INR 2-3 for 6 months after initial LMWH (until INR 2-3) | patients with symptomatic proximal DVT of the lowerlimbs confirmed by compression duplex ultrasound scan |
| |
| Tinzaparin | | vs warfarin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 0.76 [0.39 1.48] | p=1.00 | 0 | 737 | 1 | Hull, | | VTE during follow-up after active anticoagulant treatment | 1.00 [0.48 2.08] | p=1.00 | 0 | 688 | 1 | Hull, | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Hull, 2002 | LMWH, 175 IU/kg qd followed by Tinzaparin 175 IU/kg qd | UFH 5 d, followed by UFH therapeutic APTT followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT by Venography/compression ultrasonography |
| |
| Tinzaparin | | vs unfractionated heparin | Short term haemorrhage by 91% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.41 [0.16 1.08] | p=1.00 | 0 | 432 | 1 | Hull et al , | | Thrombus extension | no data | | All cause death | 0.49 [0.22 1.07] | p=1.00 | 0 | 432 | 1 | Hull et al , | | Short term haemorrhage | 0.09 [0.01 0.73] | p=0.04 | 0 | 432 | 1 | Hull et al , |
| Trial | Studied treatment | Control | Patients |
|---|
| Hull et al , 1992 | Tinzaparin Subcutaneous once daily for >= Days, 175 U/kg BID | unfractionated heparin intravenous APPTx2-3 | |
| |
| Logiparin | venous thrombosis, in all type of patients | vs twice daily logiparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 1.00 [0.02 55.80] | p=1.00 | 0 | 20 | 1 | Siegbahn, | | All cause death | 1.00 [0.02 55.80] | p=1.00 | 0 | 20 | 1 | Siegbahn, | | Bleeding | 1.00 [0.02 55.80] | p=1.00 | 0 | 20 | 1 | Siegbahn, |
| Trial | Studied treatment | Control | Patients |
|---|
| Siegbahn, 1989 | Once daily logiparin 150 XaI U/kgp, imag | twice daily logiparin 75 XaI U/kg | patients with a venographically confirmed episode of DVT |
| |
| Enoxaparin | acute coronary syndrome, in all type of patients | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death, myocardial infarction, or recurrent at 14 days | no data | | death, myocardial infarction, or recurrent at 30 days | no data | | death at 30 days | no data | | myocardial infarction at 30 days | no data | | myocardial infarction or death | no data | | recurrent angina | no data | | myocardial infarction (fatal and non fatal) | no data | | Revascularization | no data | | All cause death | no data | | Drop in platelet count of 50% | no data | | stroke (fatal and non fatal) | no data | | Minor bleeding | no data | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| RESCUE, | Enoxaparin | unfractionated heparin | patients diagnosed with acute coronary syndrome in the emergency department |
| |
| Enoxaparin | | vs tinzaparin | death, myocardial infarction, or recurrent at 30 days by 37% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| myocardial infarction or death | no data | | recurrent angina | 0.61 [0.36 1.04] | p=1.00 | 0 | 438 | 1 | EVET, | | death, myocardial infarction, or recurrent at 14 days | no data | | death, myocardial infarction, or recurrent at 30 days | 0.63 [0.40 1.00] | p=0.04 | 0 | 438 | 1 | EVET, | | death at 30 days | 0.50 [0.04 5.50] | p=1.00 | 0 | 438 | 1 | EVET, | | myocardial infarction at 30 days | 0.17 [0.02 1.38] | p=1.00 | 0 | 438 | 1 | EVET, | | myocardial infarction (fatal and non fatal) | 0.25 [0.03 2.23] | p=1.00 | 0 | 438 | 1 | EVET, | | Revascularization | no data | | All cause death | 0.50 [0.04 5.50] | p=1.00 | 0 | 438 | 1 | EVET, | | Drop in platelet count of 50% | no data | | stroke (fatal and non fatal) | no data | | Minor bleeding | no data | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| EVET, 2005 | enoxaparin, 100 IU/kg subcutaneously twice daily +aspirin for 7 days | tinzaparin, 175 IU/kg subcutaneously once daily +aspirin for 7 days | patients with non-ST-segment elevation acute coronary syndromes |
| |
| Enoxaparin | | vs UFH (on top of aspirin) | Minor bleeding by 40% adverse event Major bleeding by 15% adverse event death, myocardial infarction, or recurrent at 30 days by 17% suggested recurrent angina by 19% suggested myocardial infarction (fatal and non fatal) by 12% suggested Revascularization by 14% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death, myocardial infarction, or recurrent at 14 days | 0.84 [0.70 1.00] | p=1.00 | 0 | 3171 | 1 | ESSENCE, | | death, myocardial infarction, or recurrent at 30 days | 0.83 [0.71 0.98] | p=0.04 | 0 | 3917 | 2 | ESSENCE, INTERACT, | | death at 30 days | 0.95 [0.78 1.15] | p=1.00 | 0 | 13895 | 3 | ESSENCE, SYNERGY, INTERACT, | | myocardial infarction at 30 days | 0.89 [0.80 1.00] | p=1.00 | 0 | 13895 | 3 | ESSENCE, SYNERGY, INTERACT, | | myocardial infarction or death | 0.91 [0.83 1.00] | p=1.00 | 0 | 21715 | 5 | ESSENCE, TIMI 11 B (short term), SYNERGY, INTERACT, TIMI 11 B (long term), | | recurrent angina | 0.81 [0.66 0.98] | p=0.04 | 0 | 3917 | 2 | ESSENCE, INTERACT, | | myocardial infarction (fatal and non fatal) | 0.88 [0.79 0.97] | p=0.04 | 0 | 21715 | 5 | ESSENCE, TIMI 11 B (short term), SYNERGY, INTERACT, TIMI 11 B (long term), | | Revascularization | 0.86 [0.78 0.96] | p=0.04 | 0 | 11737 | 4 | ESSENCE, TIMI 11 B (short term), INTERACT, TIMI 11 B (long term), | | All cause death | 0.97 [0.83 1.13] | p=1.00 | 0 | 21715 | 5 | ESSENCE, TIMI 11 B (short term), SYNERGY, INTERACT, TIMI 11 B (long term), | | Drop in platelet count of 50% | 0.68 [0.45 1.03] | p=1.00 | 0 | 3171 | 1 | ESSENCE, | | stroke (fatal and non fatal) | 0.97 [0.34 2.78] | p=1.00 | 0 | 3171 | 1 | ESSENCE, | | Minor bleeding | 1.40 [1.28 1.53] | p=0.04 | 0 | 20133 | 5 | ESSENCE, TIMI 11 B (short term), SYNERGY, INTERACT, TIMI 11 B (long term), | | Major bleeding | 1.15 [1.02 1.30] | p=0.04 | 0 | 20132 | 5 | ESSENCE, TIMI 11 B (short term), SYNERGY, INTERACT, TIMI 11 B (long term), |
| Trial | Studied treatment | Control | Patients |
|---|
| ESSENCE, 1997 | enoxaparin 1mg/kg, twice daily during 48h-8days | continuous intravenous unfractionated heparin | patients with angina at rest or non–Q-wave myocardial infarction | | TIMI 11 B (short term), 1998 | enoxaprin during both the acute phase and outpatient phase | intravenous UFH for >=3 days (followed by
subcutaneous placebo injections) | unstable angina/non–Q-wave myocardial infarction | | SYNERGY, 2005 | Enoxaparin 1 mg/kg twice daily | unfractionated heparin | high-risk patients with acute coronary syndromes | | INTERACT, 2006 | enoxaparin (1 mg/kg subcutaneously twice daily) for 48 hours (+eptifibatide and aspirin) | intravenous UFH (70 U/kg bolus followed by 15 U/kg per hour adjusted to an activated partial thromboplastin time of 1.5-2 times control) for 48 hours (+eptifibatide and aspirin) | high-risk patients with ACS receiving aspirin and eptifibatide | | TIMI 11 B (long term), 1998 | enoxaprin during both the acute phase (IV) and outpatient phase (SC)
| intravenous UFH for >=3 days (followed by subcutaneous placebo injections) | unstable angina/non–Q-wave myocardial infarction
|
| |
| Enoxaparin | acute myocardial infarction, in patients eligible to receive fibrinolytic therapy | vs UFH | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.76 [0.42 1.38] | p=1.00 | 0 | 700 | 2 | HART II, Baird, | | In-hospital death | 0.83 [0.40 1.71] | p=1.00 | 0 | 700 | 2 | HART II, Baird, | | Deaths or MI | no data | | reinfarction at 30 days | 0.80 [0.48 1.35] | p=1.00 | 0 | 700 | 2 | HART II, Baird, | | death at 30 days | 0.70 [0.38 1.31] | p=1.00 | 0 | 700 | 2 | HART II, Baird, | | Major bleeding | no data | | Minor bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| HART II, 2001 | Enoxaparin 1 mg/kg BID, <=3d | UFH 4000–5000 IU bolus, then 15 IU/kg per hour for >=3d | patients undergoing reperfusion therapy with an accelerated recombinant tissue plasminogen activator regimen and aspirin for AMI | | Baird, 2002 | Enoxaparin 40 mg TID, 4 d | UFH 5000 IU bolus, then 30 000 IU over 24 h for 4d | patients receiving fibrinolytic therapy following acute myocardial infarction |
| |
| Enoxaparin | thrombosis prevention, in orthopedic surgery | vs no treatment | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Warwick, 1995 | enoxaparin 4000x1 + elastic stockings | no treatment + elastic stockings | Elective hip |
| |
| Enoxaparin | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Turpie, 1986 | Enoxaparin 3000 x2 | Placebo | Elective hip | | Leclerc, 1991 | Enoxaparin 3000 x2 | Placebo | Knee | | Samama, 1997 | enoxaparin 4000x1+elastic stockings | Placebo+elastic stockings | Elective hip | | Kalodiki, 1996 | enoxaparin 4000x1 | Placebo | Elective hip |
| |
| Enoxaparin | | vs Dextran | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| DES Group , 1991 | Enoxaparin | Dextran | Elective hip |
| |
| Enoxaparin | | vs Unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Planes , 1988 | Enoxaparin | Unfractionated heparin | Elective hip | | Levine , 1991 | Enoxaparin | Unfractionated heparin | Elective hip |
| |
| Enoxaparin | thrombosis prevention, in general surgery | vs no treatment | Bleeding by 278% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.18 [0.01 3.52] | p=1.00 | 0 | 303 | 1 | Ho [43], | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | 0.11 [0.01 2.09] | p=1.00 | 0 | 303 | 1 | Ho [43], | | wound haematoma / infection | 6.31 [0.30 132.48] | p=1.00 | 0 | 303 | 1 | Ho [43], | | transfusion | 1.43 [0.77 2.68] | p=1.00 | 0 | 303 | 1 | Ho [43], | | Bleeding | 3.78 [1.00 14.26] | p=0.04 | 0 | 303 | 1 | Ho [43], | | Major bleeding | 3.78 [0.39 36.80] | p=1.00 | 0 | 303 | 1 | Ho [43], | | All cause death | 1.89 [0.31 11.49] | p=1.00 | 0 | 303 | 1 | Ho [43], |
| Trial | Studied treatment | Control | Patients |
|---|
| Ho [43], | Enoxaparin 4000 anti-Xa units | No treatment | |
| |
| Enoxaparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.68 [0.22 2.06] | p=1.00 | 0 | 3942 | 5 | Kaaja, Gazzaniga (ISG), Nurmohamed, Gonzalez, ENOXACAN, | | asymptomatic DVT | 0.97 [0.76 1.24] | p=1.00 | 0 | 5085 | 8 | Samama 1, Samama 2, Samama 3, Gazzaniga (ISG), Nurmohamed, McLeod (Canadian), Gonzalez, ENOXACAN, | | Symptomatic venous thromboembolism (DVT, PE) | 0.58 [0.11 2.96] | p=1.00 | 0 | 892 | 3 | Samama 1, Samama 2, Samama 3, | | wound haematoma / infection | 0.66 [0.24 1.79] | p=1.00 | 0 | 68 | 1 | Kaaja, | | transfusion | 1.08 [0.83 1.41] | p=1.00 | 0 | 892 | 3 | Samama 1, Samama 2, Samama 3, | | All cause death | 0.75 [0.49 1.17] | p=1.00 | 0 | 4766 | 7 | Samama 1, Samama 2, Samama 3, Gazzaniga (ISG), Nurmohamed, Gonzalez, ENOXACAN, | | Bleeding | 0.94 [0.80 1.10] | p=1.00 | 0 | 6183 | 9 | Samama 1, Samama 2, Samama 3, Kaaja, Gazzaniga (ISG), Nurmohamed, McLeod (Canadian), Gonzalez, ENOXACAN, | | Major bleeding | 1.03 [0.72 1.47] | p=1.00 | 0 | 6183 | 9 | Samama 1, Samama 2, Samama 3, Kaaja, Gazzaniga (ISG), Nurmohamed, McLeod (Canadian), Gonzalez, ENOXACAN, |
| Trial | Studied treatment | Control | Patients |
|---|
| Samama 1, 1988 | Enoxaparin 2000 | UFH 15 000 units | General surgery | | Samama 2, 1988 | Enoxaparin 4000 | UFH 15 000 units | General surgery | | Samama 3, 1988 | Enoxaparin 6000 | UFH 15 000 units | General surgery | | Kaaja, 1992 | Enoxaparin 2000 anti Xa units | UFH 10 000 units | Gynaecological surgery | | Gazzaniga (ISG), 1993 | Enoxaparin 2000 anti Xa units | UFH 10 000 units | General and vascular surgery | | Nurmohamed, 1995 | Enoxaparin 2000 anti Xa units | UFH 15 000 units | General surgery | | McLeod (Canadian), 1995 | Enoxaparin 4000 anti Xa units | UFH 15 000 units | Colorectal surgery | | Gonzalez, 1996 | Bemiparin 2500 anti Xa units | UFH 10 000 units | Abdominal surgery | | ENOXACAN, 1997 | Enoxaparin 4000 anti Xa units | UFH 15 000 units | Abdominopelvic surgery |
| |
| Enoxaparin | thrombosis prevention, in neurosurgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | no data | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | Bleeding | 1.00 [0.27 3.75] | p=1.00 | 0 | 437 | 2 | Agnelli, Melon, | | Major bleeding | 1.00 [0.27 3.75] | p=1.00 | 0 | 437 | 2 | Agnelli, Melon, | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Agnelli, 1998 | Enoxaparin, 40 mg/d subcutaneously within 24 hours postoperatively plus compression stockings for >=7 days | compression stockings + placebo | Elective neurosurgery, 18 years or older, without excess bleeding risk | | Melon, 1987 | Enoxaparin, 20 mg/d subcutaneously 18-24 hours postoperatively for 10 days | placebo | Neurosurgery, adult, 45-90 kg of weight, without excess bleeding risk |
| |
| Enoxaparin | venous thrombosis, in all type of patients | vs acenocoumarol | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 2.00 [0.18 22.79] | p=1.00 | 0 | 100 | 1 | Veiga, | | VTE during follow-up after active anticoagulant treatment | 1.25 [0.35 4.41] | p=1.00 | 0 | 96 | 1 | Veiga, | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Veiga, 2000 | UFH, APTT 1.5–2.0d followed by Enoxaparin 4,000 IU qd | UFH, APTT 1.5–2.0d followed by Acenocoumarol target INR 2-3 | patients with objective diagnosis of DVT by Venography |
| |
| Enoxaparin | | vs coumarin | VTE during active anticoagulant treatment by 97% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 1.97 [1.06 3.66] | p=0.04 | 0 | 165 | 1 | González-Fajardo, | | VTE during follow-up after active anticoagulant treatment | no data | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| González-Fajardo, 2008 | long-term anticoagulant treatment with enoxaparin during at least 3 months | long-term anticoagulant treatment with coumarin during at least 3 months | patients with symptomatic, unilateral, first-episode DVT |
| |
| Enoxaparin | | vs warfarin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 0.62 [0.31 1.24] | p=1.00 | 0 | 453 | 3 | Pini, Gonzalez-Fajardo, Deitcher, | | VTE during follow-up after active anticoagulant treatment | 2.91 [0.96 8.85] | p=1.00 | 0 | 299 | 2 | Pini, Meyer, | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Pini, 1994 | UFH, APTT 1.3–1.9 followed by Enoxaparin 4,000 IU qd | UFH, APTT 1.3–1.9 followed by Warfarin target INR 2-3.5 | patients with objective diagnosis of DVT by Venography (diagnosed by strain-gauge plethysmography plus D-dimer latex assay and confirmed by venography) | | Gonzalez-Fajardo, 1999 | LMWH, 4,000 IU bid followed by Enoxaparin 4,000 IU qd | UFH followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT by Venography | | Meyer, 2002 | LMWH, 1.5 mg/kg qd followed by Enoxaparin 1.5 mg/Kg qd | LMWH, 1.5 mg/kg qd followed by Warfarin target INR 2-3 | patients with cancer and objective diagnosis of DVT by Venography/compression ultrasonography | | Deitcher, 2003 | LMWH: 1a, 1 mg/kg q12h; 1b, 1 mg/kg qd12h followed by Enoxaparin 1a: 1 mg/kg qd; 1b: 1.5 mg/kg qd | LMWH, 1 mg/kg q12h followed by Warfarin target INR 2-3 | patients with objective diagnosis of DVT |
| |
| Enoxaparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.14 [0.01 2.82] | p=1.00 | 0 | 134 | 1 | Simonneau et al , | | Thrombus extension | 0.14 [0.02 1.20] | p=1.00 | 0 | 134 | 1 | Simonneau et al , | | All cause death | 1.50 [0.24 9.28] | p=1.00 | 0 | 134 | 1 | Simonneau et al , | | Short term haemorrhage | 1.00 [0.02 51.15] | p=1.00 | 0 | 134 | 1 | Simonneau et al , |
| Trial | Studied treatment | Control | Patients |
|---|
| Simonneau et al , 1993 | Enoxaparin Subcutaneous twice daily for 0 Days, 100 U/kg BID | unfractionated heparin intravenous APPTx1.5-2.5 | |
| |
| Enoxaparin | | vs twice daily enoxaparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 1.51 [0.64 3.59] | p=1.00 | 0 | 610 | 1 | Merli, | | All cause death | 1.65 [0.63 4.30] | p=1.00 | 0 | 610 | 1 | Merli, | | Bleeding | 1.31 [0.35 4.92] | p=1.00 | 0 | 610 | 1 | Merli, |
| Trial | Studied treatment | Control | Patients |
|---|
| Merli, 2001 | enoxaparin 1.5 mg/kg body weight
once daily | S.c. enoxaparin at fixed dosages of 1.0 mg/kg of body weight twice daily | patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE) |
| |
| Enoxaparin | | vs UFH | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 1.05 [0.47 2.35] | p=1.00 | 0 | 588 | 1 | Merli (once daily vs UFH), | | All cause death | 1.19 [0.49 2.91] | p=1.00 | 0 | 588 | 1 | Merli (once daily vs UFH), | | Bleeding | 1.15 [0.72 1.82] | p=1.00 | 0 | 588 | 1 | Merli (once daily vs UFH), |
| Trial | Studied treatment | Control | Patients |
|---|
| Merli (once daily vs UFH), 2001 | Initial therapy with enoxaparin 1.5 mg/kg body weight
once daily
| Initial therapy with dose-adjusted intravenous
unfractionated heparin | patients with a symptomatic lower-extremity DVT confirmed by venography or ultrasonography (including patients with confirmed PE)
|
| |
| Nadroparin | acute coronary syndrome, in all type of patients | vs UFH (on top of aspirin) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death, myocardial infarction, or recurrent at 14 days | 0.99 [0.80 1.22] | p=1.00 | 0 | 2317 | 1 | FRAXIS (6days), | | death, myocardial infarction, or recurrent at 30 days | no data | | death at 30 days | 1.18 [0.77 1.80] | p=1.00 | 0 | 2317 | 1 | FRAXIS (6days), | | myocardial infarction at 30 days | 1.10 [0.77 1.55] | p=1.00 | 0 | 2317 | 1 | FRAXIS (6days), | | myocardial infarction or death | 1.04 [0.77 1.40] | p=1.00 | 0 | 4619 | 2 | FRAXIS (6days), FRAXIS (14 days), | | recurrent angina | 0.99 [0.83 1.17] | p=1.00 | 0 | 4619 | 2 | FRAXIS (6days), FRAXIS (14 days), | | myocardial infarction (fatal and non fatal) | 1.02 [0.73 1.43] | p=1.00 | 0 | 4619 | 2 | FRAXIS (6days), FRAXIS (14 days), | | Revascularization | 0.95 [0.78 1.15] | p=1.00 | 0 | 4619 | 2 | FRAXIS (6days), FRAXIS (14 days), | | All cause death | 1.18 [0.74 1.88] | p=1.00 | 0 | 4619 | 2 | FRAXIS (6days), FRAXIS (14 days), | | Drop in platelet count of 50% | no data | | stroke (fatal and non fatal) | no data | | Minor bleeding | no data | | Major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| FRAXIS (6days), 1998 | nadroparin for 6 days (+aspirin) | unfractionated heparin for 6 days (+aspirin) | unstable angina or non-Q wave myocardial
infraction | | FRAXIS (14 days), 1998 | nadroparin for 14 days
| unfractionated heparin for 14 days
| unstable angina or non-Q wave myocardial
infraction
|
| |
| Nadroparin | thrombosis prevention, in orthopedic surgery | vs no treatment | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Yoo, 1997 | nadroparin 41/kgx1 days 1-3, 62/kg x1 days 4-11+elastic stockings | no treatment | Elective hip |
| |
| Nadroparin | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| total VTE and all-cause mortality | no data | | major or clinically relevant non-major bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Sourmelis, 1995 | nadroparin 3075x1 preop, 6150x1 post op | Placebo | Hip fracture |
| |
| Nadroparin | thrombosis prevention, in general surgery | vs no treatment | asymptomatic DVT by 81% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | no data | | asymptomatic DVT | 0.19 [0.04 0.94] | p=0.04 | 0 | 61 | 1 | Marassi [41], | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | 0.35 [0.01 9.05] | p=1.00 | 0 | 64 | 1 | Marassi [41], | | transfusion | 1.15 [0.42 3.10] | p=1.00 | 0 | 64 | 1 | Marassi [41], | | Bleeding | 0.35 [0.01 9.05] | p=1.00 | 0 | 64 | 1 | Marassi [41], | | Major bleeding | no data | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Marassi [41], | Nadroparin 2850 anti-Xa units | No treatment | |
| |
| Nadroparin | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.34 [0.01 8.38] | p=1.00 | 0 | 189 | 1 | Balas [40], | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | Bleeding | 0.58 [0.16 2.04] | p=1.00 | 0 | 189 | 1 | Balas [40], | | Major bleeding | 0.20 [0.01 4.27] | p=1.00 | 0 | 189 | 1 | Balas [40], | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Balas [40], | Nadroparin 2850 anti-Xa units | Placebo | |
| |
| Nadroparin | | vs unfractionated heparin | asymptomatic DVT by 39% suggested Symptomatic venous thromboembolism (DVT, PE) by 75% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 0.20 [0.01 4.25] | p=1.00 | 0 | 344 | 1 | Barbui, | | asymptomatic DVT | 0.61 [0.40 0.93] | p=0.04 | 0 | 2917 | 5 | Kakkar and Murray, EFS, Dahan, Barbui, Eurin, | | Symptomatic venous thromboembolism (DVT, PE) | 0.25 [0.08 0.83] | p=0.04 | 0 | 2309 | 2 | Kakkar and Murray, EFS, | | wound haematoma / infection | 1.12 [0.45 2.84] | p=1.00 | 0 | 344 | 1 | Barbui, | | transfusion | 1.04 [0.84 1.29] | p=1.00 | 0 | 2309 | 2 | Kakkar and Murray, EFS, | | All cause death | 0.87 [0.44 1.72] | p=1.00 | 0 | 2309 | 2 | Kakkar and Murray, EFS, | | Bleeding | 1.00 [0.81 1.24] | p=1.00 | 0 | 2389 | 2 | EFS, Eurin, | | Major bleeding | 2.98 [0.12 73.40] | p=1.00 | 0 | 480 | 1 | Eurin, |
| Trial | Studied treatment | Control | Patients |
|---|
| Kakkar and Murray, 1985 | Nadroparin 2850 | UFH 10 000 units | General surgery | | EFS, 1988 | Nadroparin 2850 | UFH 15 000 units | Abdominal surgery | | Dahan, 1989 | Nadroparin 2850 | UFH 15 000 units | Thoracic surgery | | Barbui, 1990 | Nadroparin 2850 anti Xa units | UFH 10 000 units | General surgery | | Eurin, 1994 | Nadroparin 2850 anti Xa units | UFH 15 000 units | Abdominopelvic surgery |
| |
| Nadroparin | thrombosis prevention, in neurosurgery | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | no data | | asymptomatic DVT | no data | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | Bleeding | 3.04 [0.61 15.20] | p=1.00 | 0 | 485 | 1 | Nurmohamed, | | Major bleeding | 3.04 [0.61 15.20] | p=1.00 | 0 | 485 | 1 | Nurmohamed, | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Nurmohamed, 1996 | Nadroparin, 7500 Institute Choay anti-Xa units per day subcutaneously 18-24 hours postoperatively plus compression for 10 days | compression stockings + placebo | Craniotomy or spinal surgery for tumor or injury, 18 years or older, without excess bleeding risk |
| |
| Nadroparin | venous thrombosis, in all type of patients | vs acenocoumarol | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | no data | | puylmonary embolism | no data | | recurrent DVT | no data | | VTE during active anticoagulant treatment | 1.13 [0.43 2.97] | p=1.00 | 0 | 360 | 2 | Lopaciuk, Lopez-Beret, | | VTE during follow-up after active anticoagulant treatment | 1.16 [0.35 3.84] | p=1.00 | 0 | 345 | 2 | Lopaciuk, Lopez-Beret, | | Bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Lopaciuk, 1999 | LMWH, 85 UI/kg bid followed by Nadroparin 85 IU/kg qd | LMWH, 85 UI/kg bid followed by Acenocoumarol target INR 2-3 | patients with objective diagnosis of DVT by Venography | | Lopez-Beret, 2001 | LMWH, 1,025 IU/10 kg bid followed by Nadroparin 1,025 IU/10 kg bid | LMWH, 1,025 IU/10 kg bid followed by Acenocoumarol target INR 2-3 | patients with objective diagnosis of DVT by compression ultrasonography |
| |
| Nadroparin | | vs unfractionated heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.58 [0.24 1.43] | p=1.00 | 0 | 455 | 3 | Collaborative European Multicentre, Prandoni et al , Lopaciuk et al , | | Thrombus extension | 0.57 [0.30 1.09] | p=1.00 | 0 | 455 | 3 | Collaborative European Multicentre, Prandoni et al , Lopaciuk et al , | | All cause death | 0.58 [0.24 1.45] | p=1.00 | 0 | 455 | 3 | Collaborative European Multicentre, Prandoni et al , Lopaciuk et al , | | Short term haemorrhage | 0.85 [0.24 3.01] | p=1.00 | 0 | 455 | 3 | Collaborative European Multicentre, Prandoni et al , Lopaciuk et al , |
| Trial | Studied treatment | Control | Patients |
|---|
| Collaborative European Multicentre, 1991 | Nadroparin Subcutaneous twice daily for 10 Days, 90 U/kg BID | unfractionated heparin intravenous APPTx1.5-2 | | | Prandoni et al , 1992 | Nadroparin Subcutaneous twice daily for >=0 Days, 90 U/kg BID | unfractionated heparin intravenous APPTx1.5-2 | | | Lopaciuk et al , 1992 | Nadroparin Subcutaneous twice daily for 10 Days, 92 U/kg BID | unfractionated heparin subcutaneous twice daily APPTx1.5-2.5 | |
| |
| Nadroparin | | vs twice daily nadroparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.57 [0.29 1.15] | p=1.00 | 0 | 651 | 1 | Charbonnier, | | All cause death | 0.73 [0.31 1.74] | p=1.00 | 0 | 651 | 1 | Charbonnier, | | Bleeding | 0.62 [0.28 1.38] | p=1.00 | 0 | 651 | 1 | Charbonnier, |
| Trial | Studied treatment | Control | Patients |
|---|
| Charbonnier, 1998 | Once daily nadroparin 20,500 (AXa IU/ml)continued for at least 5 days | twice daily
nadroparin 10,250 (AXa IU/ml)continued for at least 5 days | patients with acute symptomatic proximal DVT in popliteal vein or above
documented by venography |
| |
| UFH | acute coronary syndrome, in all type of patients | vs control (on top of aspirin) | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death, myocardial infarction, or recurrent at 14 days | no data | | death, myocardial infarction, or recurrent at 30 days | no data | | death at 30 days | no data | | myocardial infarction at 30 days | no data | | myocardial infarction or death | 0.78 [0.52 1.18] | p=1.00 | 0 | 1141 | 4 | ATACS (Cohen), Holdright, RISC (heparin+aspirin vs ASP), Theroux (heparin+ASP vs ASP), | | recurrent angina | 0.74 [0.47 1.19] | p=1.00 | 0 | 526 | 3 | ATACS (Cohen), Cohen (ATACS pilot) (heparin+aspirin vs asp), Theroux (heparin+ASP vs ASP), | | myocardial infarction (fatal and non fatal) | 0.60 [0.25 1.43] | p=1.00 | 0 | 526 | 3 | ATACS (Cohen), Cohen (ATACS pilot) (heparin+aspirin vs asp), Theroux (heparin+ASP vs ASP), | | Revascularization | 1.59 [0.60 4.19] | p=1.00 | 0 | 69 | 1 | Cohen (ATACS pilot) (heparin+aspirin vs asp), | | All cause death | 1.00 [0.20 5.01] | p=1.00 | 0 | 526 | 3 | ATACS (Cohen), Cohen (ATACS pilot) (heparin+aspirin vs asp), Theroux (heparin+ASP vs ASP), | | Drop in platelet count of 50% | no data | | stroke (fatal and non fatal) | no data | | Minor bleeding | 0.86 [0.05 14.41] | p=1.00 | 0 | 69 | 1 | Cohen (ATACS pilot) (heparin+aspirin vs asp), | | Major bleeding | 1.84 [0.56 6.03] | p=1.00 | 0 | 811 | 4 | ATACS (Cohen), Holdright, Cohen (ATACS pilot) (heparin+aspirin vs asp), Theroux (heparin+ASP vs ASP), |
| Trial | Studied treatment | Control | Patients |
|---|
| ATACS (Cohen), 1994 | aspirin 162.5 mg daily plus heparin (activated partial thromboplastin time, two times control) followed by aspirin 162.5 mg daily plus warfarin (international normalized ratio, 2 to 3) for 12 weeks. | aspirin alone (162.5 mg daily) for 12 weeks. | patients with unstable rest angina or non-Q-wave myocardial infarction with last episode of pain within 48 hours of randomization and who were nonprior aspirin users | | Holdright, 1994 | intravenous heparin plus oral aspirin (150 mg once daily) | aspirin alone 150 mg/d | unstable angina | | Cohen (ATACS pilot) (heparin+aspirin vs asp), 1990 | aspirin (80 mg/day) plus heparin and then warfarin | aspirin (325 mg/day) | Patients between 21 and 75 years with unstable angina or non-Q-wave MI with last episode of pain within 48 hours of screening. | | RISC (heparin+aspirin vs ASP), 1990 | 5 days of intermittent intravenous heparin + oral aspirin 75 mg/day | oral aspirin 75 mg/day | unstable angina or non-Q-wave myocardial infarction | | Theroux (heparin+ASP vs ASP), 1988 | aspirin 325 mg/d + heparin 1000 UI/hr IV | aspirin 325 mg/d |
|
| |
| UFH | | vs placebo | myocardial infarction or death by 47% suggested recurrent angina by 58% suggested myocardial infarction (fatal and non fatal) by 89% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death, myocardial infarction, or recurrent at 14 days | no data | | death, myocardial infarction, or recurrent at 30 days | no data | | death at 30 days | no data | | myocardial infarction at 30 days | no data | | myocardial infarction or death | 0.53 [0.33 0.86] | p=0.04 | 0 | 1281 | 4 | Theroux (heparin+aspirin vs PBO), Theroux (heparin vs PBO), RISC (heparin vs PBO), RISC (ASP+ heparin vs PBO), | | recurrent angina | 0.42 [0.25 0.71] | p=0.04 | 0 | 476 | 2 | Theroux (heparin+aspirin vs PBO), Theroux (heparin vs PBO), | | myocardial infarction (fatal and non fatal) | 0.11 [0.03 0.37] | p=0.04 | 0 | 476 | 2 | Theroux (heparin+aspirin vs PBO), Theroux (heparin vs PBO), | | Revascularization | no data | | All cause death | 0.20 [0.02 1.70] | p=1.00 | 0 | 476 | 2 | Theroux (heparin+aspirin vs PBO), Theroux (heparin vs PBO), | | Drop in platelet count of 50% | no data | | stroke (fatal and non fatal) | no data | | Minor bleeding | 2.00 [0.59 6.83] | p=1.00 | 0 | 236 | 1 | Theroux (heparin vs PBO), | | Major bleeding | 1.53 [0.46 5.14] | p=1.00 | 0 | 476 | 2 | Theroux (heparin+aspirin vs PBO), Theroux (heparin vs PBO), |
| Trial | Studied treatment | Control | Patients |
|---|
| Theroux (heparin+aspirin vs PBO), 1988 | heparin (1000 units per hour by intravenous infusion)+ aspirin (325 mg twice daily) | aspirin (325 mg twice daily) | | | Theroux (heparin vs PBO), 1988 | heparin (1000 units per hour by intravenous infusion) | placebo | patients with acute unstable angina pectoris | | RISC (heparin vs PBO), 1990 | 5 days of intermittent intravenous heparin | placebo | men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction) | | RISC (ASP+ heparin vs PBO), 1990 | oral apsirin 75mg/d + intermittent IV heparin 10000UI/d followed by 7500 UI 6-hourly for 4 days | placebo
| men with unstable coronary artery disease (unstable angina or non-Q-wave myocardial infarction) |
| |
| UFH | | vs placebo (on top of aspirin) | Minor bleeding by 2090% adverse event | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death, myocardial infarction, or recurrent at 14 days | no data | | death, myocardial infarction, or recurrent at 30 days | no data | | death at 30 days | no data | | myocardial infarction at 30 days | no data | | myocardial infarction or death | 0.60 [0.17 2.13] | p=1.00 | 0 | 143 | 1 | Gurfinkel (UFH+aspririn vs aspirin), | | recurrent angina | 1.20 [0.61 2.34] | p=1.00 | 0 | 143 | 1 | Gurfinkel (UFH+aspririn vs aspirin), | | myocardial infarction (fatal and non fatal) | 0.60 [0.17 2.13] | p=1.00 | 0 | 143 | 1 | Gurfinkel (UFH+aspririn vs aspirin), | | Revascularization | 0.81 [0.28 2.31] | p=1.00 | 0 | 143 | 1 | Gurfinkel (UFH+aspririn vs aspirin), | | All cause death | 1.04 [0.02 53.29] | p=1.00 | 0 | 143 | 1 | Gurfinkel (UFH+aspririn vs aspirin), | | Drop in platelet count of 50% | no data | | stroke (fatal and non fatal) | no data | | Minor bleeding | 21.90 [1.26 381.54] | p=0.04 | 0 | 143 | 1 | Gurfinkel (UFH+aspririn vs aspirin), | | Major bleeding | 5.21 [0.29 92.25] | p=1.00 | 0 | 143 | 1 | Gurfinkel (UFH+aspririn vs aspirin), |
| Trial | Studied treatment | Control | Patients |
|---|
| Gurfinkel (UFH+aspririn vs aspirin), 1995 | aspirin plus UFH 5000 IU iv then 400 IU/kg body weight per day intravenously and titered by activated partial thromboplastin time | aspirin 200 mg/day | patients greater than 21 years with ustable angina within 24 hours of randomizationcatio |
| |
| UFH | | vs aspirin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| death, myocardial infarction, or recurrent at 14 days | no data | | death, myocardial infarction, or recurrent at 30 days | no data | | death at 30 days | no data | | myocardial infarction at 30 days | no data | | recurrent angina | 0.83 [0.29 2.42] | p=1.00 | 0 | 56 | 1 | Cohen (ATACS pilot) (heparin vs asp), | | myocardial infarction or death | 4.00 [0.39 41.11] | p=1.00 | 0 | 56 | 1 | Cohen (ATACS pilot) (heparin vs asp), | | myocardial infarction (fatal and non fatal) | no data | | Revascularization | 1.33 [0.46 3.90] | p=1.00 | 0 | 56 | 1 | Cohen (ATACS pilot) (heparin vs asp), | | All cause death | 1.33 [0.03 69.68] | p=1.00 | 0 | 56 | 1 | Cohen (ATACS pilot) (heparin vs asp), | | Drop in platelet count of 50% | no data | | stroke (fatal and non fatal) | no data | | Minor bleeding | 0.44 [0.02 11.41] | p=1.00 | 0 | 56 | 1 | Cohen (ATACS pilot) (heparin vs asp), | | Major bleeding | 1.33 [0.03 69.68] | p=1.00 | 0 | 56 | 1 | Cohen (ATACS pilot) (heparin vs asp), |
| Trial | Studied treatment | Control | Patients |
|---|
| Cohen (ATACS pilot) (heparin vs asp), 1990 | heparin followed by warfarin (without aspirin) | aspirin 325 mg/day | Patients between 21 and 75 years with unstable angina or non-Q-wave MI with last episode of pain within 48 hours of screening |
| |
| UFH | acute myocardial infarction, in patients eligible to receive fibrinolytic therapy | vs no heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 2.14 [0.64 7.16] | p=1.00 | 0 | 250 | 1 | DUCCS, | | In-hospital death | 1.43 [0.56 3.63] | p=1.00 | 0 | 250 | 1 | DUCCS, | | Deaths or MI | no data | | reinfarction at 30 days | no data | | death at 30 days | no data | | Major bleeding | no data | | Minor bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| DUCCS, 1994 | UFH no bolus, 15 IU/kg per h for 4 d; target aPTT 50–90 s | No heparin | patients with acute myocardial infarction four hours after APSAC administration, age <=85 y STEMI <=12 h |
| |
| UFH | | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| reinfarction | 0.99 [0.41 2.41] | p=1.00 | 0 | 644 | 1 | ECSG, | | In-hospital death | 0.81 [0.33 1.98] | p=1.00 | 0 | 644 | 1 | ECSG, | | Deaths or MI | no data | | reinfarction at 30 days | no data | | death at 30 days | no data | | Major bleeding | no data | | Minor bleeding | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| ECSG, 1992 | UFH 5000 IU bolus, UFH 1000 IU/h for 48–120 h | Placebo | patients treated with alteplase thrombolysis for acute myocardial infarction, Age 21–70 y STEMI <=6h |
| |
| UFH | thrombosis prevention, in neurosurgery | vs no treatment | asymptomatic DVT by 82% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Symptomatic pulmonary embolism | 1.00 [0.02 51.41] | p=1.00 | 0 | 100 | 1 | Cerrato, | | asymptomatic DVT | 0.18 [0.05 0.65] | p=0.04 | 0 | 100 | 1 | Cerrato, | | Symptomatic venous thromboembolism (DVT, PE) | no data | | wound haematoma / infection | no data | | transfusion | no data | | Bleeding | 2.00 [0.18 22.79] | p=1.00 | 0 | 100 | 1 | Cerrato, | | Major bleeding | 2.00 [0.18 22.79] | p=1.00 | 0 | 100 | 1 | Cerrato, | | All cause death | no data |
| Trial | Studied treatment | Control | Patients |
|---|
| Cerrato, 1978 | Unfractionated heparin, 5000 IU subcutaneously 3 times a day, starting 2 hours preoperatively for +7 days | no treatment | Elective neurosurgery for tumors, 40 years or older |
| |
| Heparin | venous thrombosis, in all type of patients | vs intravenous heparin | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Recurrent thromboembolic event | 0.72 [0.38 1.36] | p=1.00 | 0 | 783 | 6 | Bentley, Hull, Doyle, Walker, Lopaciuk, Pini, | | Major bleeding | 0.81 [0.40 1.64] | p=1.00 | 0 | 783 | 6 | Bentley, Hull, Doyle, Walker, Lopaciuk, Pini, |
| Trial | Studied treatment | Control | Patients |
|---|
| Krahenbuhl, 1979 | subcutaneous sodic heparin 30 000 U daily (mean) | intravenous sodic heparin 30 000 U daily (mean) | | | Bentley, 1980 | subcutaneous calcic heparin 37 000 U daily (mean) | intravenous sodic heparin 36 800 U daily (mean) | | | Andersson, 1982 | subcutaneous sodic heparin 36 800 U daily (mean) | intravenous sodic heparin 33 250 U daily (mean) | | | Hull, 1986 | subcutaneous sodic heparin 32 300 U daily (mean) | intravenous sodic heparin 29 700 U daily (mean) | | | Doyle, 1987 | subcutaneous calcic heparin 29 200 U daily (mean) | intravenous calcic heparin 29 600 U daily (mean) | | | Walker, 1987 | subcutaneous calcic heparin 29 375 U daily (mean) | intravenous calcic heparin 24 384 U daily (mean) | | | Lopaciuk, 3000 | subcutaneous sodic heparin 34 400 U daily (mean) | intravenous sodic heparin 37 000 U daily (mean) | | | Pini, 1990 | subcutaneous calcic heparin 33 800 U daily (mean) | intravenous sodic heparin 31 700 U daily (mean) | |
| |
